FLT4 antibody

Catalog No. ABIN1589828

This anti-FLT4 antibody is a Rabbit Polyclonal antibody detecting FLT4 in WB, ELISA, IP and IHC (af). Suitable for Human. This Primary Antibody has been cited in 1 publication.

Quick Overview for FLT4 antibody (ABIN1589828)

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FLT4 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunoprecipitation (IP), Immunohistochemistry (Acetone-fixed) (IHC (af))

Product Details anti-FLT4 Antibody

Purpose: VEGFR-3/FLT-4 antibody

Specificity: Recombinant human sFLT-4 (D1-7)

Characteristics: Chromosomal location: 5q35.3
Produced from sera of rabbits immunised with highly pure recombinant human soluble VEGFR-3/FLT-4 (D1-D7).

Purification: Anti-human VEGFR-3/FLT-4 was purified by antigen-affinity chromatography with immobilised soluble VEGFR-3/FLT-4.

Immunogen: Recombinant human sFLT-4 (D1-7) (ABIN1589554 and ABIN1589553)

Isotype: IgG

Application Details

Application Notes: Western Blot: Use 1-5 μg/mL

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Handling Advice: Centrifuge vial prior to opening.

Storage: 4 °C,-20 °C

Storage Comment: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Expiry Date: 24 months

References for anti-FLT4 antibody (ABIN1589828)

Liu, Li, Zhang, Rao, Liang, Liu: "The defect of both angiogenesis and lymphangiogenesis is involved in preeclampsia." in: Placenta, Vol. 36, Issue 3, pp. 279-86, (2015) (PubMed).

Target Details for FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR-3/FLT-4

Background: Vascular endothelial growth factor receptor-3, FLT4, PCL, LMPH1A, VEGFR3, fms-related tyrosine kinase 4,Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Gene ID: 2324

NCBI Accession: NM_002020, NP_002011

UniProt: P35916

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling